Volume 5.43 | Nov 3

ESC & iPSC News 5.43, November 3, 2010.
In this issue:  Science News |  Current Publications |  Industry News |  Policy News |  Events
Subscribe  |  Unsubscribe


Delta40p53 Controls the Switch from Pluripotency to Differentiation by Regulating IGF Signaling in ESCs 
Researchers discovered that delta40p53, in addition to being highly expressed in embryonic stem cells (ESCs), is the major p53 isoform during early stages of embryogenesis in the mouse. By altering the dose of delta40p53 in ESCs, researchers identified a critical role for this isoform in maintaining the ESC state. [Genes Dev]



Interested in recruiting talented individuals? Post your career opportunities in ESC & iPSC News at no cost. Contact us at [email protected]

Follow us on Twitter! @ESC_iPSC_News


Researchers Generate iPSCs to Further Treatments for Lung Disease
A team of researchers has generated 100 new lines of human induced pluripotent stem cells (iPSCs) from individuals with lung diseases, including cystic fibrosis and emphysema. [Press release from Boston University School of Medicine discussing online prepublication in Stem Cells]
MRI Contrast Agents Change Stem Cell Proliferation
When researchers tested three different labeling agents on three different stem cell populations to determine what effect the labeling agents had on stem cell phenotype, biological behavior and migration abilities, they found changes in stem cell proliferation depending on the type of contrast agent used. [Press release from EurekAlert! discussing online prepublication in Cell Transplantation]

Defining Characteristics of Bona Fide Human iPS Cells
Speaker: Sutheera Ratanasirintrawoot, PhD Candidate
G. Daley & T. Schlaeger Labs, Harvard Medical School

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

Hematopoietic Differentiation of Induced Pluripotent Stem Cells from Patients with Mucopolysaccharidosis Type I (Hurler Syndrome)
Data underscore the potential of mucopolysaccharidosis type I-induced pluripotent stem cells to generate autologous hematopoietic grafts devoid of immunologic complications of allogeneic transplantation, as well as generating non-hematopoietic cells with the potential to treat anatomical sites not fully corrected with hematopoietic cell transplantation. [Blood]
Generation of Induced Pluripotent Stem Cells Using Site-Specific Integration with Phage Integrase
Researchers describe a method using bacteriophage phi-C31 integrase to reprogram mouse embryonic fibroblasts and human amniotic fluid cells into induced pluripotent stem cells. [Proc Natl Acad Sci U S A]
Very Small Embryonic-Like Stem Cells in Cardiovascular Repair
In addition to bone marrow, very small embryonic-like cells (VSELs) were identified in several murine solid organs including the heart and brain, as well as in umbilical cord blood and peripheral blood in adult humans. Researchers hypothesized that VSELs are quiescent progeny of epiblast-derived pluripotent stem cells that are deposited during organogenesis in developing organs. [Pharmacol Ther]

Generation of Transgene-Free Lung Disease-Specific Human Induced Pluripotent Stem Cells Using a Single Excisable Lentiviral Stem Cell Cassette
Researchers report the use of a humanized version of a single lentiviral “stem cell cassette” vector to accomplish efficient reprogramming of normal or diseased skin fibroblasts obtained from humans of virtually any age. [Stem Cells]
Human Embryonic Stem Cell-Derived Microvascular Grafts for Cardiac Tissue Preservation After Myocardial Infarction
Researchers present use of a synthetic, injectable matrix metalloproteinase-responsive, bioactive hydrogel as an in situ forming scaffold to deliver thymosin beta4, a pro-angiogenic and pro-survival factor, along with vascular cells derived from human embryonic stem cells in ischemic injuries to the heart in a rat model. [Biomaterials]

Klf5 Regulates Lineage Formation in the Pre-Implantation Mouse Embryo
Findings demonstrate that Kruppel-like transcription factor (Klf) 5 is a dynamic regulator of all three lineages in the pre-implantation embryo by promoting the trophectoderm and epiblast lineages while suppressing the primitive endoderm lineage. [Development]

Effects of MRI Contrast Agents on the Stem Cell Phenotype
Labeling efficiency of three different stem cell populations (mouse embryonic stem cells, rat multipotent adult progenitor cells, and mouse mesenchymal stem cells) with three different (ultra)small superparamagnetic iron oxide particles (Resovist®, Endorem®, Sinerem®) was compared. [Cell Transplant]
Engineered Heart Tissue Enables Study of Residual Undifferentiated Embryonic Stem Cell Activity in a Cardiac Environment
Data indicate that the cardiac environment of host tissue and electrical field stimulation did not preferentially guide the differentiation of embryonic stem cell (ESCs) towards the cardiac lineage. In the same environment, injection of cardiac progenitor cells resulted in a more robust cardiac differentiation than injection of ESCs. [Biotechnol Bioeng]
Characterization of Human Huntington’s Disease Cell Model from Induced Pluripotent Stem Cells
A useful advance in Huntington’s disease (HD) would be the generation of a human-derived HD model to use for drug screening and understanding mechanisms of HD. Researchers utilized the recently established human induced pluripotent stem cell line derived from HD patient fibroblasts to derive neuronal precursors and human striatal neurons. [PLoS Curr]


Geron Awarded Grants Under Qualifying Therapeutic Discovery Project Program
Geron Corporation announced that the company has been awarded $1.2 million in grants under the Qualifying Therapeutic Discovery Project (QTDP) program. The maximum grant amount was awarded to each of the five Geron programs that were eligible for QTDP funding and included oncology and human embryonic stem cell projects. [Geron Corporation Press Release]
BioTime, Inc. Awarded $733,000 in Grants Under Qualifying Therapeutic Discovery Project Program
BioTime, Inc. announced that it has been awarded three grants totaling approximately $733,000 under the U.S. Government’s Qualifying Therapeutic Discovery Project program. [BioTime, Inc. Press Release]

Qatar to Have Region’s First Stem Cells Laboratory
Preparations are on to set up a stem cells transplant unit in Al Amal Hospital by the year-end to provide optimal care to patients in need of advanced techno-therapy and are unable to afford treatment abroad, an official source at Hamad Medical Corporation said. [The Peninsula]


Court Sets Date for Oral Arguments in Stem Cell Appeal
An appeals court in Washington, D.C. has set December 6th as the date it will hear oral arguments on whether U.S. government funding of human embryonic stem cell research should remain legal. [Court of Appeals, United States]

Another Round of Filings in Stem Cell Court Case
The paperwork continues to pile up in the lawsuit challenging the legality of the National Institutes of Health’s stem cell guidelines, the latest installments being two more briefs from attorneys on both sides. A district court judge could rule on the underlying case very soon, potentially halting research again — at least briefly. [District Court for the District of Columbia, United States]
NIH Introduces Images, a Database of Images in Biomedical Literature
More than 2.5 million images and figures from medical and life sciences journals are now available through Images, a new resource for finding images in biomedical literature. [National Institutes of Health, United States]
Korean Supreme Court Rules Stem Cells as Medicine
The Supreme Court has ruled that stem cells used to treat illnesses should be regarded as medicine that requires approval from the drug administration for use. [Supreme Court, Korea]
Cellular, Tissue and Gene Therapies Advisory Committee; Notice of Meeting [Docket No. FDA-2010-N-0001] [Food and Drug Administration, United States]
Cellular, Tissue and Gene Therapies Advisory Committee; Notice of Meeting [Docket No. FDA-2010-N-0001] [Food and Drug Administration, United States]
Request for Notification From Industry Organizations Interested in Participating in the Selection Process for Nonvoting Industry Representatives on Public Advisory Committees and Panels and Request for Nonvoting Industry Representatives on Public Advisory Committees and Panels [Docket No. FDA-2010-N-0001] [Food and Drug Administration, United States]
Change in Application Receipt Dates for AHRQ Large or Recurring Conference Grant Funding Opportunity Announcement (FOA) PAR-09-257 (NOT-HS-11-001) [Agency for Healthcare Research and Quality, United States]

Guidelines for Use of Stored Specimens and Access to Ancillary Data and Proposed Cost Schedule: Stored Biologic Specimens and Ancillary Data From the Collaborative Perinatal Project (CPP) (FR Doc. 2010-27183) [National Institutes of Health, United States]
Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-27049)[National Institutes of Health, United States]
Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-27743) [National Institutes of Health, United States]
Office of the Director, National Institutes of Health; Notice of Meeting (FR Doc. 2010-27187) [National Institutes of Health, United States]


Third Annual Research Experience of Stem Cells in European (RESCUE) Society Conference
November 8-9, 2010
Oxford, United Kingdom

Select Biosciences 2nd International Forum on Stem Cells (2010 IFSC)
November 12-13, 2010
Tianjin, China

The 16th International Conference of the International Society of Differentiation: From Stem Cells to Organisms
November 15-18, 2010
Nara, Japan

8th Annual Commercial Translation of Regenerative Medicine Conference
November 18-19, 2010
London, United Kingdom

Stem Cell Network’s 10th Annual Scientific Meeting
November 22-24, 2010
Calgary, Canada

Tissue Engineering & Regenerative Medicine International Society – North America (TERMIS-NA) 2010 Annual Conference
December 5-8, 2010
Orlando, United States

5th Annual Stem Cell Meeting on the Mesa
December 7, 2010
La Jolla, United States

Pharmacology in Stem Cells Research and Regenerative Medicine
December 17, 2010
London, United Kingdom

Biotech Showcase 2011
January 10-12, 2011
San Francisco, United States

Select Biosciences 5th Annual Stem Cells and Regenerative Medicine World Congress
January 24-25, 2011
San Diego, United States

Keystone Symposia-Stem Cells in Development, Tissue Homeostasis and Disease
January 30-February 4, 2011
Santa Fe, United States

Molecular Medicine Tri-Conference – Stem Cells: Revolutionizing Regenerative Medicine and Personalized Therapy 2011
February 23-25, 2011
San Francisco, United States

NEW 6th Annual Stem Cell Summit
March 1, 2011
New York, United States

American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer
March 3-6, 2011
Vancouver, Canada

Stem Cells, Cancer and Metastasis (C4)
March 6-11, 2011
Dillon, United States

United Kingdom National Stem Cell Network 2011 Annual Scientific Conference
March 30-April 1, 2011
York, United Kingdom

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Product Manager – Pluripotent Stem Cells (STEMCELL Technologies)

Business Manager – Centre for Blood Cell Therapies (Cell Therapies Pty Ltd)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with ESC & iPSC News at no cost.

Visit here to post your career opportunities.


 Learn more about ESC & iPSC News:  Archives |  Events |  Subscribe |  Contact Us